Pogłód R, Kraj M, Maj S
Department of Hematology, Institute of Hematology and Blood Transfusion, Warszawa, Poland.
Mater Med Pol. 1995 Jul-Sep;27(3):83-9.
15 multiple myeloma patients with severe granulocytopenia after chemotherapy were treated with recombinant human granulocyte colony stimulating factor (Neupogen; Roche). Granulocyte colony stimulating factor (G-CSF) was given s.c. usually in a dose of 5 micrograms/kg for 5-14 (median:8) days. In all cases the increase in ANC was observed; one day after completing therapy the ANC ranged from 2.3 to 19.7 (mean: 10.3) x 10(9)/l. In 3 cases the ANC peak appeared during first (2-4) days of treatment, in one- on 14-th day after 10-day unsuccesful treatment. Generally, ANCs rapidly decreased after discontinuation of treatment to the values observed prior to the last chemotherapy. Both adverse events present in 9 patients and changes in monitored blood biochemistry components were moderate and reversible. In 3 cases symptoms of myeloma progression occurred. The study showed that G-CSF is an efficient and well tolerated drug, but also demonstrated its short-term action.
15例化疗后出现严重粒细胞减少的多发性骨髓瘤患者接受了重组人粒细胞集落刺激因子（诺粒细胞刺激因子；罗氏公司）治疗。粒细胞集落刺激因子（G-CSF）通常皮下注射，剂量为5微克/千克，持续5 - 14（中位数：8）天。所有病例均观察到中性粒细胞绝对值（ANC）升高；治疗结束后一天，ANC范围为2.3至19.7（平均：10.3）×10⁹/升。3例患者的ANC峰值出现在治疗的第1（2 - 4）天，1例在10天治疗无效后的第14天出现。一般来说，停止治疗后ANC迅速降至上次化疗前观察到的值。9例患者出现的不良事件以及监测的血液生化成分变化均较轻微且可逆。3例出现骨髓瘤进展症状。该研究表明，G-CSF是一种有效且耐受性良好的药物，但也显示出其短期作用。
